In today's ACT Brief, we examine the FDA's multi-domain transparency priorities, why radiopharmaceutical trials need redesigned infrastructure, and how AI can make enrollment more predictable.
News|Podcasts|April 10, 2026
ACT Brief: Governance vs. Execution in Pharma Modernization, AI Workforce Augmentation Planning, and Adaptive Trial Regulatory Shifts
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we examine why expanding governance layers slow digital modernization initiatives, how AI will augment clinical trial roles over the next two years, and how evolving regulatory frameworks are reshaping biopharmaceutical development timelines.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In a new contributed
article , Brian Ongioni, founder of doubletheWHY, examined why pharma modernization stalls not from lack of ambition but from expanding governance layers that distance leadership from execution. Clear ownership, explicit decision rights, and proximity to implementation teams accelerate capability delivery more effectively than adding hierarchical layers focused on coordination. - In part five of his video
interview , Krishna Cheriath, vice president and head of clinical research digital data and AI at Thermo Fisher Scientific, introduced a practical augmentation scale for how AI agents will transform clinical trial roles over the next two years. Organizations need to begin workforce planning now to manage this shift effectively, moving beyond pilot thinking toward sustainable integration. - In a new Drug Digest
episode from Pharmaceutical Technology, experts from Abzena and Cellares discussed how evolving regulatory frameworks emphasize risk-based thinking and quality-by-design principles. Modern trial designs enable real-time data and informed decision-making while leveraging prior knowledge to accelerate development timelines without compromising safety standards.
That's all for today's ACT Brief. Join us next week for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine FDA input sought on early-phase ibogaine protocols, why mixed outsourcing models spread faster than oversight infrastructure, and a major partnership for a rare kidney disease treatment.
In today's ACT Brief, we examine practical guidance for clinical operations teams beginning AI adoption, how hierarchical endpoints better reflect treatment benefit, and why early-stage program failures signal smarter pipeline management.
In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
In today's ACT Brief, we examine what AI simulations surface in trial design, how RBQM delivers measurable financial returns, and three new FDA-approved treatments across hair loss, movement disorder, and bone disease.
In today's ACT Brief, we examine how AI is surfacing endpoint options beyond traditional design thinking, why sponsor oversight of outsourced work often fails on inspection despite being robust in practice, and a new combination drug for advanced kidney cancer.
Trending on Applied Clinical Trials Online
1
FDA Releases Transparency Roadmap Outlining Disclosure Priorities Across Drug Development and Regulatory Review
2
FDA Seeks Public Input on Early-Phase Clinical Trial Design for Ibogaine
3
Beyond the Molecule: Why Radiopharmaceutical Trials Require a New Operating Model
4
Operation TrialBlazer Leveraging New and Anticipated US Policy Changes in Early Development
5